In vivo, PLK1 inhibitors killed CD133(+) colon cancer cells, leading to complete growth arrest of colon cancer stem cell-derived xenografts, whereas chemotherapeutic agents only slowed tumor progression. Here, PLK1 is linked to neoplasm.